AstraZeneca announced positive results from a Phase III trial of Tagrisso in patients with relapsed non-small cell lung cancer. Tagrisso is a third-gen oral epidermal growth factor receptor (EGFR) inhibitor that targets NSCLC with the T790M mutation. Although only 10%-15% of NSCLC patients in the west have the mutation, about 50% of cases in China and east Asia do. In the trial, Tagrisso raised the median time-to-progression to 10.1 months from 4.4 months. Tagrisso, which is available in the US as a second-line treatment, is under Fast-Track review in China.
